Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Seminars in Radiation Oncology

Volumn 17, Issue 3, 2007, Pages 184-189

  Tsai, Henry K ^a   Mauch, Peter M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; CLINICAL TRIAL; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL;

ANTIGENS, CD15; ANTIGENS, CD20; DISEASE PROGRESSION; HISTIOCYTES; HODGKIN DISEASE; HUMANS; LYMPHOCYTES; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; RARE DISEASES;

EID: 34250698040     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.02.004     Document Type: Article

References (33)

1. Jackson H.J., and Parker F.J. Hodgkin's disease. II. Pathology. N Engl J Med 231 (1944) 35-44
2. Wright C.J. The "benign" form of Hodgkin's disease (Hodgkin's paragranuloma). J Pathol Bacteriol 80 (1960) 157-171
3. Smetana H.F., and Cohen B.M. Mortality in relation to histologic type in Hodgkin's disease. Blood 11 (1956) 211-224
4. Hanson T.A. Histological classification and survival in Hodgkin's disease: A study of 251 cases with special reference to nodular sclerosing Hodgkin's disease. Cancer 17 (1964) 1595-1603
5. Lukes R.J., and Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 26 (1966) 1063-1083
6. Harris N.L., Jaffe E.S., and Stein H. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
7. Diehl V., Sextro M., and Franklin J. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 17 (1999) 776-783
8. Miettinen M., Franssila K.O., and Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 51 (1983) 2293-2300
9. Regula Jr. D.P., Hoppe R.T., and Weiss L.M. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 318 (1988) 214-219
10. Mauch P.M., Kalish L.A., and Kadin M. Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis. Cancer 71 (1993) 2062-2071
11. Borg-Grech A., Radford J.A., and Crowther D. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol 7 (1989) 1303-1309
12. Bodis S., Kraus M.D., and Pinkus G. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol 15 (1997) 3060-3066
13. Leibenhaut M.H., Hoppe R.T., and Efron B. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 7 (1989) 81-91
14. Ha C.S., Kavadi V., and Dimopoulos M.A. Hodgkin's disease with lymphocyte predominance: Long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys 43 (1999) 329-334
15. Hutchings M., Loft A., and Hansen M. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol 24 (2006) 146-150
16. Hansmann M.L., Zwingers T., and Boske A. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 108 (1984) 321-330
17. Wirth A., Yuen K., and Barton M. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104 (2005) 1221-1229
18. Nogova L., Reineke T., and Eich H.T. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16 (2005) 1683-1687
19. Wilder R.B., Schlembach P.J., and Jones D. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 94 (2002) 1731-1738
20. Yahalom J., and Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 13 suppl 1 (2002) 79-83
21. Rehwald U., Schulz H., and Reiser M. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101 (2003) 420-424
22. Ekstrand B.C., Lucas J.B., and Horwitz S.M. Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood 101 (2003) 4285-4289
23. Girinsky T., Guillot-Vals D., and Koscielny S. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 51 (2001) 148-155
24. Johannsson J., Specht L., and Mejer J. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 54 (2002) 1466-1470
25. Haas R.L., Poortmans P., and de Jong D. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 21 (2003) 2474-2480
26. Haas R.L., Poortmans P., and de Jong D. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients. Eur J Cancer 41 (2005) 1724-1730
27. Pappa V.I., Norton A.J., and Gupta R.K. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol 6 (1995) 559-565
28. Crennan E., D'Costa I., and Liew K.H. Lymphocyte predominant Hodgkin's disease: A clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys 31 (1995) 333-337
29. Orlandi E., Lazzarino M., and Brusamolino E. Nodular lymphocyte predominance Hodgkin's disease: Long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma 26 (1997) 359-368
30. Feugier P., Labouyrie E., and Djeridane M. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 104 (2004) 2675-2681
31. Schlembach P.J., Wilder R.B., and Jones D. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J 8 (2002) 377-383
32. Trudel M.A., Krikorian J.G., and Neiman R.S. Lymphocyte predominance Hodgkin's disease. A clinicopathologic reassessment. Cancer 59 (1987) 99-106
33. Tefferi A., Zellers R.A., and Banks P.M. Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease. J Clin Oncol 8 (1990) 1959-1965